Background and purpose: The endocannabinoid virodhamine is a partial agonist at the cannabinoid CB 1 receptor and a full agonist at the CB 2 receptor, and relaxes rat mesenteric arteries through endothelial cannabinoid receptors. Its concentration in the periphery exceeds that of the endocannabinoid anandamide. Here, we examined the influence of virodhamine on the human pulmonary artery. Experimental approach: Isolated human pulmonary arteries were obtained during resections for lung carcinoma. Vasorelaxant effects of virodhamine were examined on endothelium-intact vessels precontracted with 5-HT or KCl. Key results: Virodhamine, unlike WIN 55,212-2, relaxed 5-HT-precontracted vessels concentration dependently. The effect of virodhamine was reduced by endothelium denudation, two antagonists of the endothelial cannabinoid receptor, cannabidiol and O-1918, and a high concentration of the CB 1 receptor antagonist rimonabant (5 mM), but only slightly attenuated by the NOS inhibitor L-NAME and not affected by a lower concentration of rimonabant (100 nM) or by the CB 2 and vanilloid receptor antagonists SR 144528 and capsazepine, respectively. The COX inhibitor indomethacin and the fatty acid amide hydrolase inhibitor URB597 and combined administration of selective blockers of small (apamin) and intermediate and large (charybdotoxin) conductance Ca 2 þ -activated K þ channels attenuated virodhamine-induced relaxation. The vasorelaxant potency of virodhamine was lower in KCl-than in 5-HT-precontracted preparations. Conclusions and implications: Virodhamine relaxes the human pulmonary artery through the putative endothelial cannabinoid receptor and indirectly through a COX-derived vasorelaxant prostanoid formed from the virodhamine metabolite, arachidonic acid. One or both of these mechanisms may stimulate vasorelaxant Ca 2 þ -activated K þ channels.
Introduction
Acute and chronic use of cannabis in human elicits complex cardiovascular effects (Jones, 2002) . In addition, an increase in the levels of endogenously formed cannabinoids has been reported in the serum of patients with septic shock (Wang et al., 2001) and with liver cirrhosis (Fernández-Rodriguez et al., 2004) . In this respect, it is important to note that endogenous cannabinoids are involved in the hypotension occurring in animal models of the latter diseases (see Pacher et al., 2006) . The mechanisms underlying the cardiovascular effects of exo-and endocannabinoids have been examined mainly in experimental animals (see Pacher et al., 2006) , and the effects of endocannabinoids on human vessels have been investigated only in a few studies. Thus, the endocannabinoid anandamide failed to relax myometrial arteries isolated from pregnant women (Kenny et al., 2002) . The same compound increased human skin microcirculatory flow; however, this effect was obtained only if it was administered on the skin and not if it was injected intravascularly (Movahed et al., 2005) . In our own hands, anandamide relaxed isolated human pulmonary artery rings (Koz"owska et al., 2007) .
Anandamide exerts its cardiovascular effects in mice and rats through cannabinoid CB 1 and CB 2 receptors and vanilloid TRPV 1 receptors (see Begg et al., 2005; Pacher et al., 2006) . In addition, it relaxes isolated blood vessels of mice and rats Wagner et al., 1999; Ho and Hiley, 2003; Offertáler et al., 2003; Milman et al., 2006) , and decreases blood pressure in mice Offertáler et al., 2003) through an as yet unidentified endothelial cannabinoid receptor, which is also activated by the cannabinoid, abn-cbd. The latter receptor appears to be involved in the effect of anandamide in the human pulmonary artery, as the vasorelaxation was mimicked by abn-cbd, and the effect of the latter was counteracted by two antagonists of the endothelial cannabinoid receptor (Koz"owska et al., 2007) . In recent years, anandamide and abn-cbd have been reported to activate the GPR55 receptor also, an orphan cannabinoid receptor (Pertwee, 2007; Ryberg et al., 2007) . However, no differences were noticed in hypotension and vasorelaxation of isolated mesenteric arteries elicited by abn-cbd between GPR55 knockout mice and their wild-type littermate controls (Johns et al., 2007) arguing against the hypothesis that the GPR55 receptor is the endothelial cannabinoid receptor.
It is possible that the endothelial cannabinoid receptor in the human pulmonary artery could be a target for the treatment of pulmonary hypertension (Koz"owska et al., 2007) . To assess further the properties of this receptor in our experimental model, we studied the effect of another endocannabinoid, virodhamine. Virodhamine (O-arachidonoyl ethanolamine) is not only a partial agonist at the CB 1 and a full agonist at the CB 2 receptor (Porter et al., 2002) , but also a full agonist at the endothelial cannabinoid receptor (Ho and Hiley, 2004 ) with a potency even slightly higher than that of abn-cbd (Ho and Hiley, 2003) . It also displays a markedly greater potency at GPR55 than at CB 1 or CB 2 receptors and a particularly high efficacy at GPR55 receptors (Pertwee, 2007; Ryberg et al., 2007; McHugh et al., 2008) . The concentration of virodhamine in peripheral tissues is two-to ninefold higher than that of anandamide (Porter et al., 2002) . For comparison, the effect of WIN 55,212-2, a synthetic agonist at CB 1 and CB 2 receptors without effect on the endothelial cannabinoid receptor (Pacher et al., 2006) , was studied as well.
Methods
All protocols were approved by the Human Ethics Committee of the Medical University of Bia"ystok.
Tissue preparation
Human lung tissue was obtained from 54 patients (46 men and 8 women, mean age 58.2 ± 0.9 years; including 78.4% smokers) undergoing lobectomy or pneumonectomy during resection of lung carcinoma. Preoperative echocardiography revealed normal left and right ventricular function in each case. Patients did not have any clinical evidence of pulmonary hypertension nor did they receive b-blockers. Before the operation, all patients received cephalosporins and low-molecular-weight heparin as anti-infection and antithrombotic prophylaxis, respectively. The tissue was transported to the laboratory within half an hour in cold (4 1C), pregassed Tyrode's bicarbonate solution (for composition, see below). Lobar and segmental pulmonary artery branches were cleaned from lung parenchyma and cut into rings (from the middle portion of each artery; 3-5 mm length and 2-4 mm outer diameter).
Organ bath technique
The arterial rings were suspended on stainless steel wires in 10 mL organ baths containing Tyrode's solution (concentration in mM: NaCl, 139.2; KCl, 2.7; CaCl 2 , 1.8; MgCl 2 , 0.49; NaHCO 3 , 11.9; NaH 2 PO 4 , 0.4; glucose, 5.5 and pH 7.4), gassed continuously with 95% O 2 and 5% CO 2 , at 37 1C. Pulmonary artery rings were allowed to equilibrate for 90 min; during this time period, the bath fluid was changed every 10 min with fresh Tyrode's solution. The optimal resting tension was 2-2.5 g (depending on the rings' internal diameter), which ensured that responses to agonists were maximal. Muscle tension was recorded by a force displacement transducer (PIM 100RE, BIO-SYS-TECH, Bia"ystok, Poland) and displayed on a computer.
Concentration-response curves
After the equilibration period, all rings were constricted submaximally with phenylephrine (10 mM) to prime the tissues and to check the functionality of the endothelium (at least 80% relaxation in response to acetylcholine 1 mM). When the endothelium was not required, vessels were denuded by rubbing the intimal surface mechanically, and successful endothelial removal was confirmed by a lack of vasorelaxant response to acetylcholine. To examine the vasorelaxant effect of virodhamine, WIN 55,212-2 and iloprost, arteries were constricted submaximally with 5-HT (creatinine sulphate complex; 0.5-1.2 mM; for details see Table 1 ) or high K þ (60 mM) Tyrode's solution, which was prepared by equimolar substitution of NaCl by KCl. Then cumulative concentration-response curves to virodhamine were constructed. To examine the mechanisms involved in the vasorelaxant effect of virodhamine, rings were treated for 30 min with the following antagonists and enzyme or ion channel inhibitors: cannabidiol 3 mM and O-1918 10 mM (putative endothelial cannabinoid receptor; Koz"owska et al., 2007) ; and rimonabant 100 nM and 5 mM (CB 1 receptor and putative endothelial cannabinoid receptor, respectively; Járai et al., 1999; O'Sullivan et al., 2004) ; SR 144528 1 mM (CB 2 receptor; Zoratti et al., 2003) , capsazepine 5 mM (vanilloid TRPV 1 receptor; Járai et al., 1999) ; indomethacin 10 mM (COX; Koz"owska et al., 2007) ; L-NAME 300 mM (NOS; Koz"owska et al., 2007) In control tissues, the respective vehicles were used instead. In each individual preparation, only one experimental curve was determined.
To examine the antagonistic properties of virodhamine against 5-HT-induced contraction, some rings were treated for 30 min with one concentration (10 mM) of virodhamine or its vehicle (control tissues), and then a concentration-response curve for 5-HT (0.01-100 mM) was constructed.
Calculations and statistical analysis
The relaxation produced with virodhamine, WIN 55,212-2 and iloprost or their solvents was expressed as the percentage relaxation of the precontraction induced by 5-HT or KCl. To determine the potency of agonists, EC 50 values (that is, the concentrations causing the half maximum effect) were determined from the individual concentration-response curves. A series of experimental procedures markedly attenuated the vasodilator effect of virodhamine. To have a rough measure for its potency under such conditions, the concentration causing a relaxation of 25% of the precontracted vessel was determined (EC 25 Results are expressed as means ± s.e.mean of n experiments. Statistical analyses were performed using the t-test for unpaired data. When two or more treatment groups were compared with the same control, ANOVA followed by Dunnett's test was used. Differences were considered as significant when Po0.05.
Drugs used (À)-Phenylephrine hydrochloride, acetylcholine chloride, 5-HT, apamin, charybdotoxin, L-NAME, indomethacin (Sigma, Munich, Germany) were dissolved in deionized water with the exception of 5-HT (dissolved in 0.1 N HCl) and indomethacin (dissolved in 0.5 M NaHCO 3 ). Iloprost (Schering AG, Berlin, Germany) was dissolved in 0.9% NaCl. Virodhamine, (À)-cannabidiol, capsazepine (Tocris, Bristol, UK), O-1918 (1,3- 
was dissolved in a mixture of water and DMSO (4:6).
Results
General 5-HT (0.01-100 mM) induced a concentration-dependent contraction of human pulmonary artery rings (pEC 50 ¼ 5.98 ± 0.26; Figure 1 ). Virodhamine (10 mM) failed to modify the concentration-response curve for 5-HT (pEC 50 ¼ 6.24 ± 0.21; Figure 1 ).
The vasorelaxant effects of virodhamine, WIN 55,212-2 and iloprost on the human pulmonary artery were examined -nitro-L-arginine methyl ester, ND, not determined because the extent of vasorelaxant effect of virodhamine is very low under this condition. Data are expressed as means ± s.e.mean. ***Po0.001, compared with control rings (with intact endothelium; as determined by one-way ANOVA followed by Dunnett's post hoc test) precontracted with 5-HT (1 mM).
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H Koz"owska et al in vascular rings precontracted with 5-HT using a concentration of 1 mM (that is, approximately equivalent to its EC 60 ) or with 60 mM KCl (virodhamine only); the majority of the experiments was carried out on preparations precontracted with 5-HT. As L-NAME, indomethacin and K þ channel blockers slightly increased and cannabidiol slightly decreased the resting tension of pulmonary rings by themselves, a reduced (0.5-1 mM) and higher (1-1.2 mM) concentration of 5-HT was used, respectively (for details, see Table 1 ). Virodhamine (0.1-100 mM) and the other drugs under study did not affect the tone of vessels not precontracted with 5-HT, when given alone (results not shown).
Vasorelaxant effect of virodhamine and WIN 55,212-2 As shown in Figure 2 , the endocannabinoid virodhamine (0.1-100 mM), but not its vehicle (0.01-1% v/v; ethanol), produced a concentration-dependent relaxation of endothelium-intact isolated human pulmonary arteries precontracted with 5-HT (for original traces, see Figure 2a ). A full relaxation (96.2±3.1%, n ¼ 37; expressed as percentage of relaxation of the tone induced by 5-HT 1 mM) was induced by the highest concentration of the agonist. The pEC 50 value for the vasorelaxant effect of virodhamine in vessels precontracted with 5-HT was 5.07 ± 0.07 (n ¼ 37). We did not observe any differences in virodhamine-elicited relaxation of 5-HT-precontracted human pulmonary arteries isolated from smokers and non-smokers; this refers to the potency (pEC 50 of 5.08 ± 0.09 (n ¼ 29) and 5.14 ± 0.10 (n ¼ 8), respectively) and the maximum effect (results not shown). The vasorelaxant effect of virodhamine was gradual and it took 46.5 ± 4.1 min (n ¼ 37) to construct complete concentrationresponse curves. Influence of cannabinoid and TRPV 1 receptor antagonists on the virodhamine-induced relaxation Two antagonists of the putative endothelial cannabinoid receptor, cannabidiol (3 mM) and O-1918 (10 mM), shifted the concentration-response curve for virodhamine to the right by factors of 13.8 and 11.5 (Figure 3a) , yielding estimated pK b values of 6.65±0.17 (n ¼ 5) and 6.26±0.17 (n ¼ 5), respectively (for the respective pEC 25 values, see Table 1 ). In contrast, O-1918 (10 mM) did not affect the relaxant effect of the stable analogue of prostacyclin (PGI 2 ), iloprost (0.1-100 mM; mean pEC 50 values for iloprost were 5.43 ± 0.14 (n ¼ 5) and 5.24 ± 0.14 (n ¼ 5) in control and O-1918-treated rings (Figure 3b) ).
The vasorelaxant effect of virodhamine was not modified by the CB 1 receptor antagonist rimonabant given at a concentration of 100 nM, known to block CB 1 receptors. However, a higher concentration of this antagonist (5 mM), which also antagonizes endothelial cannabinoid receptors, produced a 5.1-fold shift to the right of the concentrationresponse curve of virodhamine (Figure 4a Virodhamine relaxes human pulmonary arteries H Koz"owska et al value was 5.87 ± 0.28 (n ¼ 5; for the respective pEC 25 value, see Table 1 ). The CB 2 receptor antagonist SR144528 (1 mM) and the TRPV 1 receptor antagonist capsazepine (5 mM) failed to affect virodhamine-induced relaxations (Figure 4b ).
Influence of endothelium removal, L-NAME, indomethacin and URB597 on the virodhamine-induced relaxation The virodhamine-induced vasorelaxation of endotheliumintact human pulmonary arteries was attenuated by the COX inhibitor indomethacin (10 mM), which shifted its concentration-response curve to the right by a factor of 9.1 (Figure 5a ). The NOS inhibitor L-NAME (300 mM) only slightly attenuated the vasorelaxant effect of the three highest concentrations of virodhamine; a statistically significant influence was noticed for virodhamine 30 mM only (Figure 5a ; see Table 1 for pEC 25 values). The FAAH inhibitor URB597 (1 mM) produced a 5.9-fold rightward shift of the concentration-response curve for virodhamine ( Figure 6 ; for pEC 25 values, see Table 1 ). Removal of endothelium (which completely abolished the relaxation induced by acetylcholine 1 mM; data not shown) strongly reduced the vasorelaxant effect of virodhamine (Figure 5b ), which amounted to 37.6 ± 6.2% of relaxation of the precontracted vessels at 100 mM (n ¼ 11). Pretreatment of endothelium-denuded rings with the combination of O-1918 (10 mM), indomethacin (10 mM) and the FAAH inhibitor URB597 (1 mM) did not further amplify the inhibitory effect of endothelium removal on the vasorelaxant response to virodhamine (Figure 5b ).
Influence of KCl (60 mM) and of K þ channel blockers on the virodhamine-induced relaxation Next, the vasodilator effect of virodhamine was studied in endothelium-intact human pulmonary arteries precon- 
SR144528 (1 µM)
Figure 4 Influence of rimonabant (a), SR144528 and capsazepine (b) on the concentration-response curve of virodhamine for its relaxant effect on 5-HT-precontracted endothelium-intact human pulmonary arteries. Results are expressed as percentage relaxation of the isometric contraction induced by 5-HT. Means±s.e.mean of 5-37 tissues for each curve. *Po0.05, ***Po0.001 compared with the respective control (virodhamine alone; as determined by one-way ANOVA followed by Dunnett's post hoc test). In few cases, s.e.mean is smaller than or equal to the size of symbols.
Virodhamine relaxes human pulmonary arteries H Koz"owska et al tracted with KCl (60 mM) and its effect in 5-HT-precontracted vessels was compared. KCl (60 mM) induced an increase in vessel tone comparable to that elicited by 5-HT (1 mM; see Table 1 ). However, it markedly attenuated the virodhamineinduced relaxation, reducing its effect obtained for the highest dose of the agonist to 15.9 ± 2.2% (n ¼ 4; Figure 7 ). For this reason, we were not able to determine the pEC 25 value for the vasorelaxant effect of virodhamine in KClprecontracted vessels. Figure 7 
Discussion
This study was carried out to further characterize the cannabinoid-induced vasorelaxation of the human pulmonary artery described by Koz"owska et al. (2007) and is based on experiments with virodhamine, an endocannabinoid and WIN 55,212, a synthetic cannabinoid receptor agonist. To precontract the human pulmonary artery rings, we used 5-HT because of the extensive physiological function of endothelium in this circulatory bed and also because of the fact that 5-HT has a major function as vasoconstrictor in the pulmonary circulation (Dempsie and MacLean, 2008) . The 5-HT-induced contraction of the human pulmonary artery is predominantly, if not exclusively, related to the activation of 5-HT 2A receptors (Koz"owska et al., 2007) .
Receptor involved in the virodhamine-induced relaxation
Virodhamine caused full relaxation of the endotheliumintact isolated human pulmonary artery. The majority (80%) of the pulmonary arteries used in our study were obtained from smokers and this might mean that the effect of virodhamine represents an abnormal rather than the real physiological response. This possibility, however, is very unlikely as there was no difference in the response to this agonist in tissue taken from smoking and non-smoking patients. As observed in abn-cbd (Koz"owska et al., 2007) , the relaxation elicited by virodhamine developed slowly and, for both of these agonists, the construction of the complete Means ± s.e.mean of 5-37 arteries for each curve. *Po0.05, ***Po0.001 compared with the respective control (virodhamine alone in endothelium-intact rings; as determined by one-way ANOVA followed by Dunnett's post hoc test). In few cases, s.e.mean is smaller than or equal to the size of symbols. Means±s.e.mean of 7-37 arteries for each curve. *Po0.05, **Po0.01, ***Po0.001 compared with the respective control (virodhamine alone; as determined by the t-test for unpaired data). In many cases, s.e.mean is smaller than or equal to the size of symbols.
Virodhamine relaxes human pulmonary arteries H Koz"owska et al concentration-response curves took about 50 min. However, in comparison with abn-cbd, virodhamine exhibited a higher potency (pEC 50 4.80 ± 0.06; n ¼ 23, and 5.07 ± 0.07; n ¼ 37, respectively; Po0.01). Similar differences in the potencies of abn-cbd and virodhamine were also observed in the rat mesenteric artery (pEC 50 6.2 and 6.4; Hiley, 2003, 2004) . Note that the level of potencies of the two agonists is higher in the rat mesenteric artery Hiley, 2003, 2004) than in the human pulmonary artery (Koz"owska et al., 2007; this study) . Importantly, the two endocannabinoids studied so far in the human pulmonary artery, anandamide (Koz"owska et al., 2007) and virodhamine (this study), exhibited higher potencies than the synthetic cannabinoid abn-cbd and, in contrast with abn-cbd, did not relax the basal tone by themselves (Koz"owska et al., 2007; this study). Which type of receptor was involved in the vasorelaxant effect of virodhamine? First, the most trivial explanation, namely that this effect is because of antagonism of the 5-HT used to precontract the vessels, can be excluded as virodhamine (10 mM) did not modify the contractor response of the pulmonary artery rings to 5-HT. Second, the lack of a vasorelaxant effect of WIN 55,212-2 argues against the involvement of CB 1 and CB 2 receptors in the effect of virodhamine. The involvement of CB 1 receptors can also be excluded as the selective CB 1 receptor antagonist rimonabant did not influence the effect of virodhamine at a concentration of 100 nM at which it antagonizes CB 1 receptor-mediated effects in rat resistance and conduit arteries . Moreover, the CB 2 receptor antagonist SR 144528, used at a concentration of 1 mM known to block CB 2 receptor-mediated response in calf pulmonary endothelial cells (Zoratti et al., 2003) , failed to modify the response to virodhamine. Third, the possibility that virodhamine acts through TRPV 1 receptors (at which it exhibits a modest effect; Ho and Hiley, 2004) can be excluded because the selective TRPV 1 receptor antagonist capsazepine did not affect the virodhamine-induced relaxation in a concentration range at which it antagonizes TRPV 1 receptor-mediated effects, for instance, in the rat mesenteric artery . Fourth, the involvement of the recently characterized GPR55 receptor in the effect of virodhamine had also to be considered, as it is an agonist at this receptor (Pertwee, 2007; Ryberg et al., 2007; McHugh et al., 2008) . However, this possibility is very unlikely as recent experiments with a GPR55 receptor knockout mouse clearly showed that this receptor does not lead to a vasodilator response (Johns et al., 2007) . Nevertheless, the GPR55 receptor might occur in the pulmonary, as opposed to the systemic, circulation or in human, as opposed to rodent, blood vessels.
Experiments with three antagonists at the endothelial cannabinoid receptor suggest that this receptor was involved in the vasorelaxant effect of virodhamine. Cannabidiol and O-1918 antagonized the effect of virodhamine at concentrations at which they had been previously shown to antagonize the endothelial cannabinoid receptor-mediated vasodilatation in the rat mesenteric (Ho and Hiley, 2003) or human pulmonary artery (Koz"owska et al., 2007) . Cannabidiol has a low affinity for cannabinoid CB 1 and CB 2 receptors in binding studies, but a moderate potency as a non-competitive antagonist against CB 1 and CB 2 receptor agonists (Thomas et al., 2007) . O-1918 does not bind to CB 1 or CB 2 receptors and does not induce relaxation up to 30 mM (Offertáler et al., 2003) and may be superior to cannabidiol as an antagonist of endothelial cannabinoid receptors. Interestingly enough, both antagonists exhibited a higher potency in the human pulmonary artery towards virodhamine (this study) when compared with abn-cbd (Koz"owska et al., 2007) The respective pA 2 values were 6.6 and 5.9 for cannabidiol and 6.3 and 5.1 for O-1918 (for the possible explanation of this discrepancy, see below). The inhibitory effect of the higher concentration of rimonabant (5 mM) against the vasorelaxant effect of virodhamine in the human pulmonary artery is also compatible with the involvement of the endothelial cannabinoid receptor in this effect Wagner et al., 1999; Ho and Hiley, 2003) .
Endothelial mechanisms involved in the virodhamine-induced relaxation
The vasorelaxant effect of virodhamine (this study), like that of abn-cbd (Koz"owska et al., 2007) , is endothelium-dependent, that is, removal of the endothelium reduces the vasorelaxant effect of both agonists by about 50% in the human pulmonary artery. In contrast, the vasorelaxant effect of virodhamine was reduced by about 80% in the endothelium-denuded rat mesenteric artery (Ho and Hiley, 2004) . Thus, the vasorelaxant action of virodhamine, similar to that of abn-cbd, consists of an endothelium-dependent and endothelium-independent component. In this study, we focused on the endotheliumdependent action of virodhamine. Means±s.e.mean of 4-37 arteries for each curve. *Po0.05, ***Po0.001 compared with the respective control (that is, 5-HT-precontracted arteries not exposed to K þ channel blockers; as determined by one-way ANOVA followed by Dunnett's post hoc test). In many cases, s.e.mean is smaller than or equal to the size of symbols.
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The next question addressed was which endotheliumderived vasodilator(s) is (are) involved in the virodhamineinduced vasodilator effect. The endothelial cannabinoid receptor is usually connected to the release of endothelium-derived hyperpolarizing factor, as shown in animal models (see Randall et al., 2004) and in the human pulmonary artery (Koz"owska et al. 2007) . Two sets of experiments show that this mechanism is also implicated in the vasorelaxant effect of virodhamine in this study. 
The effect of virodhamine might also be related to nitric oxide, one of the main endothelial vasodilators (Moncada and Higgs, 2006) . However, in our hands, L-NAME, an inhibitor of the biosynthesis of nitric oxide by endothelial cells, caused only a modest inhibition of the vasorelaxant effect of the highest concentrations of this endocannabinoid, suggesting that nitric oxide has only a minor function in the effect of virodhamine. Nitric oxide is not involved at all in the vasorelaxant effects of virodhamine in the rat mesenteric artery (Ho and Hiley, 2004) and of abn-cbd in the human pulmonary artery (Koz"owska et al. 2007 ).
An additional mechanism involved in the virodhamine-induced relaxation The possibility that the effect of virodhamine is related to the increased formation of PGI 2 (or another vasorelaxant product of COX activity) had also to be considered. This was likely as the virodhamine-induced vasorelaxation was attenuated by indomethacin, an inhibitor of COX. This effect might be because of an increase in COX activity following the activation of the endothelial cannabinoid receptor. There is, however, an entirely different possibility to account for this phenomenon, that is, that arachidonic acid formed from virodhamine is converted to PGI 2 . This latter possibility is suggested by a series of our results.
The endocannabinoids known so far are derivatives of, and are degraded to, arachidonic acid from which vasorelaxant metabolites may be formed. The vasodilator effect of anandamide in bovine (Pratt et al., 1998) and sheep coronary arteries (Grainger and Boachie-Ansah, 2001 ) or in rabbit mesenteric arteries (Fleming et al., 1999 ) is related to this mechanism. Unfortunately, very little is known, at present, of the degradation pathways for virodhamine (Porter et al., 2002; De Petrocellis et al., 2004) . It has been reported that, in human neocortex, this endocannabinoid can interact with FAAH (Steffens et al., 2005) , an enzyme known to hydrolyse anandamide to arachidonic acid. In our studies, we used the selective and potent FAAH inhibitor URB597 (Di Marzo et al.,
2005
) at a concentration of 1 mM, which has been shown to amplify the relaxation of the rat small mesenteric arteries to anandamide, but not that to 2-arachidonoylglycerol, another endocannabinoid (Ho and Randall, 2007) . We found that blockade of FAAH by URB597 attenuated the vasorelaxant effect of virodhamine. This finding is in harmony with the concept of the involvement of this enzyme in the metabolism of virodhamine. However, the effect of URB597 was unexpected at first glance. We would have even expected an increase in the vasorelaxant effect of virodhamine because of its impaired degradation and increased availability in the biophase of the endothelial cannabinoid receptor.
The formation of a vasorelaxant COX product may also explain why the effect of virodhamine is attenuated by indomethacin, whereas that of abn-cbd is not. Abn-cbd, unlike virodhamine, is chemically not related to arachidonic acid. Moreover, the differential potency of the two antagonists, cannabidiol and O-1918, against virodhamine and abn-cbd may be caused by the fact that in the case of virodhamine, the antagonist under study is competing with a much lower concentration of the endocannabinoids, as a considerable amount of the compound has already been degraded. This phenomenon will lead to an erroneous increase of the estimated pK b value. Finally, the fact that either enzyme inhibitor produced a similar effect on the virodhamine-related vasorelaxation may support the view that the two enzymes affect two subsequent steps of a metabolic pathway (although this phenomenon might be accidental as well). To our knowledge, this is the first report to demonstrate that the effects of virodhamine are sensitive to inhibition of FAAH or COX. We can exclude the possibility that virodhamine acts only through its vasorelaxant metabolite as O-1918, the antagonist of the endothelial cannabinoid receptor, inhibited the relaxation induced by virodhamine but not that elicited by iloprost, a stable PGI 2 analogue. Interestingly, when endothelium-denuded human pulmonary arteries were exposed to O-1918, indomethacin plus URB597, the vasorelaxant effect of virodhamine was not attenuated suggesting that both its direct vasorelaxant effect through the endothelial cannabinoid receptor and its indirect effect through an endogenously formed prostanoid are connected with intact endothelium.
We have already suggested (Koz"owska et al. 2007 ) that the endothelial cannabinoid receptor may be a target for the treatment of pulmonary hypertension. A drug like virodhamine may offer a particular advantage over abn-cbd, as it has a dual action. It is of interest in this context that PGI 2 receptor agonists are already in use for the treatment of this disorder in humans (Naeije and Huez, 2007) .
Conclusions
Virodhamine causes a full, slowly developing relaxation of the isolated human pulmonary artery. This effect is partially dependent on vascular endothelium and results from two mechanisms, such as the activation of the putative endothelial cannabinoid receptor (but not of cannabinoid CB 1 , CB 2 or vanilloid receptors and probably not of the GPR55 receptor) and the hydrolysis of virodhamine to arachidonic Virodhamine relaxes human pulmonary arteries H Koz"owska et al acid and subsequent production of a vasorelaxant prostanoid through COX. One or both of these mechanisms may stimulate vasorelaxant Ca 2 þ -activated K þ channels. In the periphery, the concentration of virodhamine is higher than that of anandamide. Thus, its ability to relax human pulmonary arteries suggests that it may be a candidate for controlling vascular tone under physiological or pathophysiological conditions or even for therapeutic purposes.
